1 completed, 1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Bloodstream Infection (BSI): new trials by email Literature Review of Bloodstream Infection (BSI) trials Research Report on Bloodstream Infection (BSI)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam) - Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 80 | 2025-04-12 | 2025-07-30 |
| Prolonged Cardiopulmonary Bypass Time as Predictive Factor for in Hospital Infection Bloodstream Infection (BSI) | Completed | University Hospital, Basel, Switzerland | 7064 | 2020-09-01 | 2021-11-02 |
Sepsis (2) · Cross Infection (1)
Infections (2) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Systemic Inflammatory Response Syndrome (2) · Disease Attributes (1) · Iatrogenic Disease (1)
Qilu Pharmaceutical Co., Ltd. (1) · University Hospital, Basel, Switzerland (1)
China (1) · Switzerland (1)